BioStem Technologies Navigates Market Pressures with Strategic Acquisition and Strong Margins

BioStem Technologies, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, revealing significant market challenges offset by strategic moves aimed at future growth. The company generated net revenue of $10.1 million for the fourth quarter, representing a 55% decrease compared to Q4 2024. This decline was attributed to reimbursement uncertainty and competitive pressure in the physician office and mobile settings. Despite the revenue drop, BioStem maintained a gross margin of 97%, reflecting a product mix shift toward products without licensing fees.

The company reported a GAAP net loss of $11.3 million for the quarter, compared to net income of $14.7 million in Q4 2024. Adjusted EBITDA was $3.4 million, down from $11.0 million in the prior year period. For the full year 2025, net revenue was $47.5 million compared to $69.7 million in 2024, with gross profit of $44.4 million representing 94% of net revenue. The annual results were impacted by lower wound care volume and a charge for potentially uncollectible accounts receivable from Venture Medical.

A key development was the January 2026 acquisition of BioTissue Holdings Inc. surgical and wound assets, which significantly expanded BioStem's product portfolio and commercial footprint. The acquisition diversifies the company's end markets into the hospital setting and integrates approximately 20 direct sales representatives and managers along with more than 30 independent sales agents. CEO Jason Matuszewski stated that this move creates a fundamentally stronger and more diversified regenerative medicine company positioned to navigate the evolving reimbursement landscape.

The company provided a financial outlook for 2026, anticipating first quarter revenue in the range of $5 million to $6 million. This reflects expected performance of the newly acquired hospital business in line with historical levels and a significant decline in the physician office business. BioStem expects to drive sequential and year-over-year growth in the hospital business during the second half of 2026 as integration activities are completed and the salesforce expands. The company also sees potential for sequential revenue growth improvement in the physician office market as it begins to stabilize later in the year.

BioStem continues to pursue a Nasdaq uplisting, having appointed KPMG LLP as its independent registered public accounting firm in October 2025. The company expects to have audited financial statements for 2024 and 2025 in the near future, which represents a key prerequisite for the uplisting process. As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million following the closing of the BioTissue asset acquisition on January 21, 2026. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, with compliance established in accordance with current Good Tissue Practices and current Good Manufacturing Processes. For more information about the company's products and technologies, visit https://biostemtechnologies.com.